艾司西酞普兰剂量与疗程对健康老年人脑脊液Aβ水平的影响
这项对照临床试验在114名认知正常老年人中比较艾司西酞普兰与安慰剂对脑脊液β-淀粉样蛋白42(Aβ42)的影响。结果显示,艾司西酞普兰治疗组脑脊液Aβ42较安慰剂组多降低9.4%(p<0.001,95%CI 4.9%-14.2%)。基线Aβ阳性者Aβ42降低幅度较小。
要点
- 艾司西酞普兰可降低认知正常老年人脑脊液Aβ42水平。
- 治疗组较安慰剂组Aβ42多降低9.4%,效应量为0.81。
- 基线Aβ阳性者(CSF Aβ42<250 pg/mL)降低幅度较小。
核心结论
- 短期艾司西酞普兰治疗可降低认知正常老年人的脑脊液Aβ42水平。
研究设计与样本
- 研究为对照临床试验,纳入114名认知正常老年人,随机分配至安慰剂组、20 mg艾司西酞普兰2周组、20 mg艾司西酞普兰8周组或30 mg艾司西酞普兰8周组。
- 治疗前后通过腰椎穿刺采集脑脊液,以个体内Aβ42百分比变化作为主要结局指标。
主要发现
- 艾司西酞普兰治疗组脑脊液Aβ42较安慰剂组多降低9.4%(p<0.001,95%CI 4.9%-14.2%,d=0.81)。
- 基线Aβ阳性(CSF Aβ42<250 pg/mL)与较小的Aβ42降低相关(p=0.006,95%CI -16.7%至0.5%,d=-0.52)。
关键数值与推荐
- 基线Aβ阳性定义为脑脊液Aβ42水平<250 pg/mL,Aβ阴性定义为>250 pg/mL。
临床怎么用
- 在认知正常老年人中,艾司西酞普兰可降低脑脊液Aβ42,提示其可能作用于AD预防的靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether treatment with escitalopram compared with placebo would lower CSF β-amyloid 42 (Aβ42) levels. RATIONALE: Serotonin signaling suppresses Aβ42 in animal models of Alzheimer disease (AD) and young healthy humans. In a prospective study in older adults, we examined dose and treatment duration effects of escitalopram. METHODS: Using lumbar punctures to sample CSF levels before and after a course of escitalopram treatment, cognitively normal older adults (n = 114) were assigned to placebo, 20 mg escitalopram × 2 weeks, 20 mg escitalopram × 8 weeks, or 30 mg escitalopram × 8 weeks; CSF sampled pretreatment and posttreatment and within-subject percent change in Aβ42 was used as the primary outcome in subsequent analyses. RESULTS: An overall 9.4% greater reduction in CSF Aβ42 was found in escitalopram-treated compared with placebo-treated groups (p < 0.001, 95% confidence interval [CI] 4.9%-14.2%, d = 0.81). Positive baseline Aβ status (CSF Aβ42 levels <250 pg/mL) was associated with smaller Aβ42 reduction (p = 0.006, 95% CI -16.7% to 0.5%, d = -0.52) compared with negative baseline amyloid status (CSF Aβ42 levels >250 pg/mL). CONCLUSIONS: Short-term longitudinal doses of escitalopram decreased CSF Aβ42 in cognitively normal older adults, the target group for AD prevention. CLINICALTRIALSGOV IDENTIFIER: NCT02161458. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for cognitively normal older adults, escitalopram decreases CSF Aβ42.
引用
- Sheline YI, Snider BJ, Beer JC, et al. Effect of escitalopram dose and treatment duration on CSF Aβ levels in healthy older adults: A controlled clinical trial. Neurology. 2020. PMID: 32913021. doi:10.1212/WNL.0000000000010725
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。